InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Accelerates Development Strategy for Lead Candidate
June 11, 2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, was featured in a recent article that discussed the company’s efforts beginning a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity […]
InvestorNewsBreaks – Why SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’
May 21, 2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, is positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. “Blockbuster drugs such as […]
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in NetworkNewsAudio Editorial on Next-Generation GLP-1 Therapies
May 15, 2026
This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in a NetworkNewsAudio audio press release examining the evolution of the GLP-1 treatment market, highlighting the company’s development of GEP-44, a patented next-generation metabolic therapy designed to improve on first-generation GLP-1 drugs. […]
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Emerging GLP-1 Innovation
May 14, 2026
This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) announced its featured placement in a BioMedWire editorial examining next-generation innovation in the rapidly expanding GLP-1 therapeutic market. The editorial highlights the company’s subsidiary GlucaPharm Inc. and its development of GEP-44, a novel triple agonist peptide designed to enhance efficacy, tolerability and delivery flexibility in the […]
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
May 13, 2026
This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) was featured in BioMedWire editorial coverage examining the rapid growth of the GLP-1 market, with the company highlighted for its subsidiary GlucaPharm Inc. and its development of GEP-44, a patented triple agonist peptide […]
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation
May 12, 2026
This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) announced its placement in a BioMedWire editorial examining the evolution of GLP-1 therapies and emerging innovation in obesity and metabolic disease treatment. The editorial highlights SureNano’s subsidiary GlucaPharm Inc. and its GEP-44 program, a novel triple agonist peptide designed to improve efficacy, tolerability and delivery flexibility in the […]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’
May 12, 2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano (CSE: SURE) (OTCQB: SURNF) is a Canadian life sciences company positioning itself within one of the most significant pharmaceutical developments of this generation: the rapid rise of GLP-1–based therapies for obesity and metabolic disease. Blockbuster drugs such as Ozempic(R), […]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advancing a Differentiated Next-Gen GLP-1 Platform
May 12, 2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include paid advertising. NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) — via BioMedWire — SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and […]
SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44
May 11, 2026
Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano Science (CSE: SURE) (OTCQB: SURNF), a Canadian life sciences company, has begun a key phase of preclinical development for its lead drug candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes. The company is initiating […]
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Next-Generation GLP-1 Candidate as Obesity Drug Market Expands Rapidly
May 11, 2026
This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF), through subsidiary GlucaPharm Inc., is advancing GEP-44, a patented triple agonist peptide targeting GLP-1 and peptide YY receptors as the global obesity and metabolic disease market continues to expand. The company is pursuing a differentiated approach focused on improved efficacy, tolerability and […]
InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances GEP-44 Toward IND-Enabling Studies, Expands Investor Outreach
April 24, 2026
This article has been disseminated on behalf of SureNano Science Ltd. and may include paid advertising. SureNano Science (CSE: SURE) (OTCQB: SURNF) announced plans to initiate a U.S. Food and Drug Administration IND-enabling GLP toxicology and pharmacology program for its lead candidate GEP-44, to be conducted with LabCorp, aimed at supporting future Phase I clinical trials. […]